ClinPhone Acquires DataLabs
Nottingham, UK – October 27, 2006 – ClinPhone, the global leader in clinical technology solutions, today announced the acquisition of DataLabs, a premier Electronic Data Capture (EDC) vendor. This enables ClinPhone to become the first company in the biopharmaceutical sector to offer a comprehensive suite of clinical trial management and data capture systems. The deal could be worth up to $68.768 million (approximately £36.5 million) to the shareholders of DataLabs if the company meets certain performance targets. All employees within its current headquarters in Irvine, CA and its satellite operations office in Conshohocken, PA will integrate into the ClinPhone organization.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.